Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsClinical potential of pacritinib in the treatment of myelofibrosisNovel therapies for myelofibrosisEfficacy of ruxolitinib for myelofibrosis.A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine TumorsThe Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.Emerging role of epigenetics in systemic sclerosis pathogenesis.Quality of life in MPN comes of age as a therapeutic target.Panobinostat: first global approval.Emerging drugs for the treatment of myelofibrosis.Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Myelofibrosis: an update on drug therapy in 2016.Management of myelofibrosis: JAK inhibition and beyond.A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).Developmental Therapeutics in Myeloproliferative Neoplasms.Novel Therapies for Myelofibrosis.Pharmacotherapy of Myelofibrosis.Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.
P2860
Q26738514-538CC39C-1351-491F-9A24-2CF1DF376B57Q26752940-1778D85D-753D-478B-92E7-A8255B7D9CFDQ26766319-87801C65-7AAF-4353-ACDF-9B0A62F313B3Q26796450-B5F1AEE8-4D2B-48D9-BFBB-A80E8F21A004Q28081693-4CEC6398-2B99-4458-8BFF-E431B1B5D256Q33415489-CF74D0BB-2DD1-4AC3-B447-A9B4798AFD09Q33432714-95D52603-7CD7-4FFB-8DF7-EF2F8754D210Q35856790-26EE5FFF-483C-460C-BE50-8A709F5F5583Q36150377-135FB080-B126-4AF1-AAD4-DDA50A573838Q36539785-72E4061C-5AD6-41D9-A6B9-BD221431CA1AQ37708936-F47497C4-36C7-45D6-9EAB-482D06F13A2FQ38230244-4E572C1F-4540-44D8-96D2-26AC301438B3Q38254893-BDFB42CC-F34A-4E72-9242-AA126226E70BQ38403118-B20B4BF3-11DD-4764-B1D8-3F10874193F8Q38543775-D85A0264-BBEA-4550-B843-2DB532E131EEQ38567540-7EE35394-AD50-4736-B0BF-BCB48D6E411AQ38984578-C6764D8A-1161-4AA5-9327-FD9382FBD053Q38989215-86755CF2-5C8F-419F-8365-5F7B13A37C49Q39232415-901D85A6-F520-4942-8E5F-973E66FE9980Q42551329-7E175B5D-A5D1-4EAB-9061-ECBAC6A6FDD0Q43753697-460A8F99-4A30-4A7D-B8B7-09DBDB7A82EBQ48008083-8E280962-5DB1-438D-AE7E-8CCBC38CB08BQ52817185-B9EBBDEC-3514-4D46-934E-A140FFE86F92Q53119304-48419FA8-7FDE-4CFA-BBA0-2867CA6DA379Q55071119-37141D86-2228-41C5-8C9D-7E62E9861064
P2860
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@ast
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@en
type
label
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@ast
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@en
prefLabel
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@ast
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@en
P2093
P2860
P356
P1476
Phase II trial of panobinostat ...... ycythaemia vera myelofibrosis.
@en
P2093
Carole Paley
Daniel J DeAngelo
David S Snyder
Ellen K Ritchie
Jessica Rine
Kapil N Bhalla
Kebede Begna
Michael S Ondovik
Ruben A Mesa
Siddhartha Ganguly
P2860
P304
P356
10.1111/BJH.12384
P407
P577
2013-05-23T00:00:00Z